Former Fierce Markets writer and current independent writer Arsalan Arif recently published the latest ranking of global CRO companies. Let me share with you here that the ranking is based on market value. The data source is mainly based on the financial reports of listed companies, while the unlisted companies are estimated by reliable information sources (unit: billion US dollars). Since the founding of our company in 2004, Medicilon has grown into one of the professional drug discovery contract research organizations (CRO) in China.
Quintiles has undoubtedly continued to rank No. 1 in the market value ranking of CRO companies. Dennis Gillings co-founded Quintiles with several other partners in 1982. Quintiles has since been involved in clinical trials of pharmaceutical companies. With expertise and expertise in clinical trials, business capabilities surpassed employers, and soon became one of the few CRO companies in the world, until now Quintiles is still the world’s largest CRO company.
After the CRO industry has undergone a series of integrations, many small companies have merged into large companies. The gap between companies has gradually narrowed and industry competition has become increasingly fierce. The areas covered by the entire CRO industry service are also expanding. From candidate compounds, to early clinical trials, to the final market promotion, CRO companies participate in the entire process. As the entire industry continues to evolve, many outstanding companies have come to the fore, including PPD, Parexel, Icon, PRA Health Sciences, Covance, INC Research / inVentiv Health, and local company Wuxi AppTec (Wuxi).
In order to keep itself in an invincible position in the fierce competition, strengthen the integration with cross-fields, especially highlight the strategic position of data resources, last year, Quintiles and IMS Health completed the merger, IMS Health is the world’s largest provider of doctor prescription data , Also provides drug pricing and market services for pharmaceutical companies.
Another way to strengthen itself is through synergies between peers, including LabCorp’s acquisition of Covance, and the merger of INC and inVentiv Health.
This time, the CRO companies are ranked from the perspective of market capitalization. Both the market capitalization data and the number of employees are derived from corporate documents/financial reports, and the deadline is set on August 30. The two companies ranked 10th, which is for reference by the original author. The conclusion reached after the opinions of industry professionals.
QuintilesIMS
Market value: $20.7 billion
2016 revenue: $5.4 billion
Number of employees: 50,000
CEO: Ari Bousbib
LabCorp/Covance
Market value: $15.66 billion
2016 LabCorp revenue: $6.6 billion
Covance in 2016: $2.8 billion
Number of LabCorp employees: 36,000
Number of Covance employees: 16,000
LabCorp CEO: David King
Covance CEO: John Ratliff
PPD
Estimated value: 9.05 billion US dollars
Number of employees: 19,000
CEO: David Simmons
Icon
Market value: $6.08 billion
2016 revenue: $1.7 billion
Number of employees: 12,500
CEO: Steve Cutler
INC Research/inVentiv Health
Market value: $6.04 billion
2016 revenue: $2.1 billion
Number of employees: 22,000
CEO: Alistair Macdonald
PRA Health Sciences
Market value: $4.8 billion
2016 revenue: $1.8 billion
Number of employees: 13,000
CEO: Colin Shannon
PAREXEL
Market value: $4.5 billion
2016 revenue: $2.1 billion
Number of employees: 18,900
CEO: Josef von Rickenbach
BioClinica
Estimated value: 1.4 billion US dollars
CEO: John Hubbard
Medpace
Market value: $1.2 billion
2016 revenue: $371 million
Number of employees: 2,500
CEO: August Troendle
Premier Research
CEO: Ludo Reynders
Worldwide Clinical Trials
CEO: Neal Cutler
Reference source: The top10 biopharma CROs in the world—mid-2017 edition
Original Title: Global TOP10 CRO Companies (2017 Mid Edition)
Related Articles:
TOP 10 New CRO Companies in China
评论
发表评论